TrialLeukemia2022

Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.

Robert Seifert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.